On Monday, Avidity Biosciences Inc (NASDAQ: RNA) opened lower -4.10% from the last session, before settling in for the closing price of $26.57. Price fluctuations for RNA have ranged from $22.24 to $56.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 49.32% over the past five years. Company’s average yearly earnings per share was noted -32.24% at the time writing. With a float of $111.14 million, this company’s outstanding shares have now reached $119.89 million.
Let’s look at the performance matrix of the company that is accounted for 391 employees. In terms of profitability, gross margin is 87.81%, operating margin of -3477.44%, and the pretax margin is -2957.72%.
Avidity Biosciences Inc (RNA) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Avidity Biosciences Inc is 7.55%, while institutional ownership is 103.94%. The most recent insider transaction that took place on Apr 01 ’25, was worth 163,486. In this transaction Chief Program Officer of this company sold 5,875 shares at a rate of $27.83, taking the stock ownership to the 50,554 shares. Before that another transaction happened on Mar 20 ’25, when Company’s Chief Medical Officer sold 9,578 for $31.06, making the entire transaction worth $297,491. This insider now owns 72,850 shares in total.
Avidity Biosciences Inc (RNA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -32.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.06% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Check out the current performance indicators for Avidity Biosciences Inc (RNA). In the past quarter, the stock posted a quick ratio of 15.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 281.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.90, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -4.30 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Avidity Biosciences Inc (NASDAQ: RNA) saw its 5-day average volume 2.33 million, a positive change from its year-to-date volume of 1.45 million. As of the previous 9 days, the stock’s Stochastic %D was 14.34%. Additionally, its Average True Range was 2.31.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 3.87%, which indicates a significant decrease from 12.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.25% in the past 14 days, which was higher than the 69.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.22, while its 200-day Moving Average is $38.67. Nevertheless, the first resistance level for the watch stands at $27.20 in the near term. At $28.93, the stock is likely to face the second major resistance level. The third major resistance level sits at $30.40. If the price goes on to break the first support level at $24.00, it is likely to go to the next support level at $22.53. Assuming the price breaks the second support level, the third support level stands at $20.80.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
There are currently 120,212K shares outstanding in the company with a market cap of 3.06 billion. Presently, the company’s annual sales total 10,900 K according to its annual income of -322,300 K. Last quarter, the company’s sales amounted to 2,970 K and its income totaled -102,260 K.
